Cite
Lombardi P, Rossini D, Crespi V, et al. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treat Rev. 2021;103:102326doi: 10.1016/j.ctrv.2021.102326.
Lombardi, P., Rossini, D., Crespi, V., Germani, M. M., Bergamo, F., Pietrantonio, F., Santini, D., Allegrini, G., Daniel, F., Pagani, F., Antoniotti, C., Zaniboni, A., Conca, V., Latiano, T. P., Boccaccino, A., Passardi, A., Tamburini, E., Masi, G., Di Maio, M., & Cremolini, C. (2021). Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer treatment reviews, 103102326. https://doi.org/10.1016/j.ctrv.2021.102326
Lombardi, Pasquale, et al. "Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature." Cancer treatment reviews vol. 103 (2021): 102326. doi: https://doi.org/10.1016/j.ctrv.2021.102326
Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature. Cancer Treat Rev. 2021 Dec 23;103:102326. doi: 10.1016/j.ctrv.2021.102326. Epub 2021 Dec 23. PMID: 35016085.
Copy
Download .nbib